Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27586618 | 0.96 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2PRKCEPRKCQ | |
| SCHEMBL170304 | 0.96 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2PRKCEPRKCQ | |
| SCHEMBL519027 | 0.96 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2PRKCEPRKCQ | |
| SCHEMBL438865 | 0.96 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2PRKCEPRKCQ | |
| SCHEMBL7072490 | 0.96 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2PRKCEPRKCQ | |
| SCHEMBL251871 | 0.96 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2PRKCEPRKCQ | |
| SCHEMBL519182 | 0.96 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2PRKCEPRKCQ | |
| SCHEMBL7994536 | 0.96 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2PRKCEPRKCQ | |
| SCHEMBL251323 | 0.96 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2PRKCEPRKCQ | |
| SCHEMBL249433 | 0.93 | LMNA (0.39) | ALDH1A1CNR1CNR2LMNAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663183-B1 | SOLID PHARMACEUTICAL DOSAGE FORM COMPRISING RITONAVIR | ABBOTT LAB (US) | 2011-07-13 | — | — | EP | claimed |
| EP-2444070-A1 | Tablets | Abbott Laboratories (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120022089-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2407179-A1 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT | Kowa Company, Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20120004305-A1 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT | KOWA CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| US-20120004306-A1 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT | KOWA CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| US-20110319399-A1 | EXTERNAL PREPARATION CONTAINING ANALGESIC/ANTI-INFLAMMATORY AGENT | KOWA CO., LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2389172-A1 | ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION | Abbott Gmbh & Co., Kg (DE) | 2011-11-30 | — | — | EP | disclosed |
| EP-2386293-A1 | Process for producing a solid dispersion of an active ingredient | Abbott GmbH & Co. KG (DE) | 2011-11-16 | — | — | EP | disclosed |
| EP-1996163-B1 | PROCESS FOR PRODUCING A SOLID DISPERSION OF AN ACTIVE INGREDIENT | ABBOTT GMBH & CO KG (DE) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011068723-A1 | ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| EP-2283844-A1 | A solid pharmaceutical dosage formulation comprising lopinavir | Abbott Laboratories (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20110015216-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110008430-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100239521-A1 | METHOD FOR THE PREPARATION OF MICRO- AND NANO-SIZED CARRIER SYSTEMS FOR THE ENCAPSULATION OF BIOACTIVE SUBSTANCES | MOZAFARI MOHAMMAD REZA | 2010-09-23 | — | — | US | disclosed |
| US-20100021540-A1 | Tablets and Preparation Thereof | ABBOTT LABORATORIES (US) | 2010-01-28 | — | — | US | disclosed |
| EP-1725215-B1 | METHOD AND APPARATUS FOR PRODUCING CARRIER COMPLEXES | UNIV LIVERPOOL JOHN MOORES (GB) | 2007-07-25 | — | — | EP | disclosed |
| EP-1725215-A1 | METHOD AND APPARATUS FOR PRODUCING CARRIER COMPLEXES | Liverpool John Moores University (GB) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005084641-A1 | METHOD AND APPARATUS FOR PRODUCING CARRIER COMPLEXES | LIVERPOOL JOHN MOORES UNIVERSITY (GB) | 2005-09-15 | — | — | WO | disclosed |
| US-5183601-A | Mixture of polyoxazoline and surfactant | KAO CORPORATION (JP) | 1993-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021540-A1 | Tablets and Preparation Thereof | GRN, EXOSC9, ALG3 | ALDH1A1 3606/4885CNR1 1862/4885CNR2 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.